Vivet’s First Gene Therapy Product, VTX 801 for Wilson’s Disease, Receives European and US Orphan Drug Designation
Vivet Therapeutics, announced today that both the Food and Drug Administration (FDA) and the European Commission (EC) have granted Orphan Drug Designation (ODD) for Vivet’s lead gene therapy product, VTX-801, for the treatment of Wilson’s Disease (WD), a chronically debilitating and life-threatening condition if not treated.
“This designation validates Vivet’s efforts to treat the copper metabolism disorder, Wilson’s Disease. The FDA and EC have both recognized the unmet need for a safe and effective treatment of Wilson’s Disease by physiological restoration of copper homeostasis and the potential of VTX 801 to address such need" stated Jean-Philippe Combal, CEO of Vivet Therapeutics.
VTX-801 is Vivet’s first gene therapy product to be granted Orphan Drug Designation. This is an important value driver for Vivet, in particular through the 10 & 7-years market exclusivity in the EU & US respectively if VTX-801 is approved for the treatment of Wilson’s Disease. Initiation of clinical development is planned for Q4 2018 in both the US and the EU.
“Through our strategic collaboration with Fundación para la Investigación Médica Aplicada (FIMA) at the Centro de Investigación Medica Aplicada (University of Navarra, Spain), we are building an unparalleled platform to address key challenges in gene therapy, notably improving sustainability and immune tolerance, targeting Wilson’s Disease and other hepatic rare metabolic genetic disorders. A critical asset to this platform is a new liver targeting AAV-Anc80 serotype, licensed from Massachusetts Eye and Ear (MEE), a teaching hospital of Harvard Medical School, Boston" added Jean-Philippe Combal.
For more information, visit www.vivet-therapeutics.com
About VTX-801 : VTX-801 is an adeno-associated virus (AAV) containing a gene coding for a functional mini-ATP7B copper transporter, that is intended to restore copper metabolism through liver cell targeting.
About WiIson’s Disease : Wilson’s disease is an inherited orphan disorder affecting approximately 1:40,000 individuals. In this condition, the physiological copper biliary elimination pathway is disrupted, leading to tissue accumulation of toxic copper levels, most notably in liver and CNS. Onset of symptoms typically occurs in teenagers or in young adults and left untreated, the condition uniformly progresses to severely debilitating complications and death. The disease is due to inactivating mutations in the gene encoding the copper transporter ATP7B.
About Vivet Therapeutics : Vivet Therapeutics is a gene therapy biotech company with headquarters in Paris, France, dedicated to the research, development and future commercialization of gene therapy products for inherited liver disorders with high medical need.
Media & Investor:
Thomas Daniel, +33 6 68 88 38 60
Business Development Director
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
CA-PELLEPHARM20.11.2018 12:02 | Pressemeddelelse
LEO Pharma and PellePharm Announce $760 Million Collaboration to Advance Innovative Therapies for Rare Skin Diseases
IDEMIA20.11.2018 10:02 | Pressemeddelelse
IDEMIA Provides SK Telecom in South Korea with GMSA Compliant Smart Connect Solution to Activate and Manage eSIM Device Lifecycles
AURAK20.11.2018 08:53 | Pressemeddelelse
AURAK Hosts ICEWES 2018
IPSEN/3BP20.11.2018 07:32 | Pressemeddelelse
Ipsen and 3BP announce First Patient Dosed in Phase I/II study for first-in-class radionuclide (IPN01087)
GEMALTO20.11.2018 07:02 | Pressemeddelelse
Gemalto Expands Data Center Footprint in Europe to Support Cloud-Based Access Management Services
UAE-MINISTRY-OF-INTERIOR19.11.2018 22:15 | Pressemeddelelse
Saif bin Zayed Inaugurates Interfaith Alliance for Safer Communities: Child Dignity in the Digital World Forum
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum